Three years ago, malady the FDA approved Johnson & Johnson’s thermocool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.
By Mary Stuart

Read or Download Article